Achalasia-Like Disease with Esophageal Pressurization in a Myasthenic Dog

J. Kempf, K. Beckmann, and P.H. Kook

**Key words:** Gastroenterology; Gastrointestinal tract; Immunology; Motility and function; Neurology; Neuromuscular disorders.

An 8-year-old, intact male Pug was examined for a 7-day history of progressive weakness, progressive decline in food intake, dysuria, and dysphonia. The dysuria was described as an inability to void when being walked as the dog could not lift its leg and did not urinate although there was evidence of urine leakage in the dog’s blankets. When initially examined, the dog was alert with a BCS of 5/9. The physical examination did not reveal abnormalities. Results of hematology, serum biochemistry, and urinalysis as well as abdominal ultrasound did not reveal abnormalities. Upon owners’ request, the dog was discharged without further work-up, and gabapentina (5 mg/kg, PO q12h) were prescribed for suspected lumbosacral pain. Because of increasing weakness over the next 2 days, the dog was presented at an emergency clinic, where urinary retention caused by lumbosacral disease was suspected and treated with a single dose of dexamethasoneb (10 mg IM). Three days later, the dog was again examined for anorexia and progressive weakness. Physical examination revealed an alert dog able to walk 2–3 m with a stiff gate and kyphotic posture before finally lying down.

Laboratory work revealed a CK (111 U/L; reference range, 51–191) within reference range and no abnormalities were detected on urinalysis. A bacterial culture of urine showed no growth. Thoracic radiographs revealed moderate esophageal dilatation and a markedly dilated stomach (Fig 1). Results of a neurologic examination were consistent with a neuromuscular junction disorder, and an edrophonium chloride challenge (0.2 mg/kg IV) showed a dramatic positive response. At the time of electromyographic testing, an upper gastrointestinal endoscopy was also performed because of concerns about steroid-induced gastric ulceration.

Before anesthesia, esophageal high-resolution manometry (HRM) was used to evaluate esophageal function (Fig 2). A manometric catheter was lubricated with 2% lidocaine gel and carefully inserted intranasally. It was passed through the nasopharynx into the esophagus and finally positioned so that it recorded the pressure profile of the entire esophagus from the pharynx to the stomach. Real-time pressure imaging enabled accurate placement, and 3–4 pressure sensors were positioned intragastrically to rule out artifacts caused by breathing-related movements of the esophagogastric junction. HRM examination revealed an abnormal swallowing mechanism: after normal upper esophageal sphincter (UES) relaxation (UES residual pressure 0.4 mmHg [–10.5 to 0.3 mmHg], UES relaxation time to nadir 138 mmHg (58–140 mmHg), relaxation duration 300 ms [145–305 ms]) the aborally propagating peristaltic waves of the tubular esophagus, as well as lower esophageal sphincter (LES) relaxations [LES baseline pressure 37.3 mmHg (14.6–45.1 mmHg), LES residual pressure 27 mmHg (1.9–19.1 mmHg)] were completely absent throughout the study. The peristaltic waves were discontinued by simultaneous contractions of the tubular esophagus beginning at a point just past the first third of the tubular esophagus (Fig 3). The subsequent esophagogastroduodenoscopy did not reveal abnormalities except for a dilated and flaccid esophagus.

Biopsies were taken from the middle and lower esophagus, stomach, and duodenum. Histopathologically, all esophageal, gastric, and duodenal biopsies did not reveal abnormalities. Electromyographic examination of the limbs and epaxial muscles did not reveal abnormalities. Supramaximal repetitive nerve stimulation of the tibial and ulnar nerve at a frequency of 3 Hz produced a decrement of 30% (reference <10%). At this point, myasthenia gravis (MG) was suspected on the basis of clinical, electromyographic, and pharmacologic testing results. After treatment with pyridostigminb (1.5 mg/kg PO, q8h), the dog had progressive improvement of all clinical findings. By the time the AChR titer came back negative (0.22 nmol/L; normal <0.6 nmol/L) on day 14, the dog had already fully recovered. Upon recheck on day 21, the dog’s owners had already stopped pyridostigmin 4 days...

---

**Abbreviations:**

- AChR: acetylcholine receptor
- HRM: high-resolution manometry
- LES: lower esophageal sphincter
- MG: myasthenia gravis
previously. Weakness, anorexia, dysphonia, and dysuria had all completely resolved, and the dog appeared bright and alert. The owners agreed to a repeated HRM study of the esophagus that did not reveal abnormalities of esophageal function and swallowing (Fig 4). The dog’s clinical signs had not recurred at the time of writing (12 months later).

Discussion

This report describes a dog with an achalasia-like condition of the esophagus caused by MG. Achalasia is associated with functional loss of myenteric plexus ganglion cells in the distal esophagus and is the most well-defined esophageal motility disorder in people where it is characterized by the absence of distal esophageal peristalsis and inadequate LES relaxation. Achalasia can be subtyped into 3 groups based on manometric esophageal body pressure profiles. Type 1 is the complete absence of peristaltic contractile activity and minimal pressurization. Type 2 denotes the absence of peristaltic contractile activity with pan-esophageal pressurization, and type 3 is characterized through spastic esophageal contractions. Histopathologic findings vary in humans with achalasia. The majority of endoscopic esophageal biopsies of achalasic patients are normal, whereas an increased number of intraepithelial lymphocytes is found in patients with primary end-stage achalasia. Our esophageal biopsies comprising epithelium and lamina propria did not reveal abnormalities. This could have been caused by the comparatively acute onset of the disease, or because of the unrepresentative endoscopic biopsies. Another possibility might have been the pretreatment with a high dose of corticosteroids.

After reviewing existing criteria for seronegative MG classification in dogs, we strongly believe the dog

Fig 1. Left lateral (A) and dorsoventral (B) radiographs illustrating a dilated esophagus filled with fluid and gas and a marked gastric distension, filled with a large amount of gas.

Fig 2. Physiologic swallow pressure topography of a healthy Beagle extending from the pharynx to the stomach, shown in the Mano-view software program. Examination was performed with a 36-channel-circumferential solid-state probe with 10-mm spacing between adjacent sensors. The colors reflect the intensity of the pressures; red stands for high and blue for low pressure (color scale on the left side). Upper esophageal sphincter and LES are clearly detectable as high pressure zones. There is a relaxation of both sphincters after a swallow. The figure on the right side shows the schematic position of the catheter in the body. LES, lower esophageal sphincter.
described here had seronegative MG, because of the clinical signs consistent with MG, positive edrophonium response, decremental response of the compound muscle action potential, and normalization of limb muscle weakness after anticholinesterase treatment. In humans, dysuria occurs in myasthenic patients, and there is also evidence for this in dogs. It has been hypothesized that this is because of autoantibodies directed against ganglionic acetylcholine receptors in the autonomic nervous system. Another explanation would be the existence of both muscarinic and nicotinic antibodies that could have blocked contractions of the detrusor muscle.

Possible explanations for the negative antibody titer result could include the prior treatment with an immunosuppressive dose of corticosteroid medication, early onset of disease with clinical signs preceeding seropositivity causing the titer to rise and become positive upon repeated testing, antibodies directed against non-AChR end-plate determinants, or antibodies

---

**Fig 3.** Swallow pressure topography extending from pharynx to stomach shown in the Manoview software program. Examination was performed with a 36-channel-circumferential solid-state probe with 10-mm spacing between adjacent sensors. The 2 swallows demonstrate rapid compartmentalized pressurization extending from the lower two-thirds of the tubular esophagus to the closed LES. No normal peristalsis was seen during the entire manometric examination. (recording speed: 15 s/page). UES, upper esophageal sphincter; LES, lower esophageal sphincter; PIP, pressure inversion point.

**Fig 4.** Swallow pressure topography 15 days after the initial abnormal HRM (Fig 3) extending from pharynx to stomach, shown in the Manoview software program. Examination was performed with a 36-channel-circumferential solid-state probe with 10-mm spacing between adjacent sensors. The illustrated swallow represents a physiologic swallow with normal esophageal function. (recording speed: 15 s/page). UES, upper esophageal sphincter; LES, lower esophageal sphincter; PIP, pressure inversion point.
bound to end plates without detectable circulating serum antibodies.\textsuperscript{14} It would have been ideal to repeat determination of an AChR titer,\textsuperscript{9} but additional samples were not sent because of the rapid response to treatment, and comparatively long turnaround time with overseas shipping. Although less frequently observed, very rapid improvements can be seen with MG in dogs.\textsuperscript{5} Further, the complete resolution of all clinical signs is also compatible with an underlying diagnosis of MG.\textsuperscript{9}

In humans, HRM constitutes the gold standard for evaluating esophageal function. Utilizing color-coded pressure topography, HRM quickly enables the examiner to obtain an impression of the integrity of the whole swallowing act. Because of the closely spaced pressure sensors, the whole esophagus can be visualized at the same time, from the pharynx to the LES (Fig 2). In addition, HRM is a noninvasive technique, and its feasibility in awake healthy dogs has recently been evaluated by the authors.\textsuperscript{1} The unexplained clinical presentation (ie, refusal to eat) together with the suspicion of MG, which can cause dysphagia, provided the indication for manometric assessment of the dog’s esophageal function. The HRM findings were consistent with what has been described as achalasia type II with pansophageal pressurization in humans.\textsuperscript{15} Strikingly, a similar phenomenon could also be documented in the present case, even though humans and dogs differ in their esophageal muscle composition. Although the entire tubular esophagus is composed of striated muscle in dogs, most of the canine LES consists of smooth muscle.\textsuperscript{16} Relaxation of the LES is mediated by a release of acetylcholine from the presynaptic nerve endings, followed by an activation of inhibitory motor neurons.\textsuperscript{17} This activation occurs predominantly via nicotinic and muscarinic receptors and the inhibiting neurotransmitter is nitric oxide.\textsuperscript{17} In the dog described here, bound AChR antibodies could have led to blocking of the LES relaxation. The esophagus seems to be able to overcome a closed LES with an adaptive mechanism, the pansophageal pressurization, a condition in which the entire esophageal lumen is pressurized between the 2 sphincters.\textsuperscript{18} In humans, achalasia type II patients have aperistalsis, but preserved muscularis propria longitudinal muscle contraction and sufficient excitation of the circular muscle to generate substantial intrabolus pressure in the esophageal body to result in bolus transport.\textsuperscript{15} This pressure phenomenon seems to be the major mechanism of esophageal emptying in people suffering from achalasia.\textsuperscript{18} Also, in the present case, this mechanism could have allowed the dog to propel ingested food into its stomach. The underlying pathomechanism that triggers the longitudinal muscle contractions has so far not been elucidated in human achalasia. In humans, it is known that the pressurization action is perceived as very painful. It is usually described as a concurrent chest pain.\textsuperscript{19,20} We believe this could also explain the anorexia in the dog described in this report. It is possible that refusal to eat was because of the accompanying pain during the act of swallowing. The same observation of painful swallowing occurs in dysphagic myasthenic humans with achalasia.\textsuperscript{21–23}

In summary, this is a report of achalasia-like disease secondary to suspected seronegative MG, and clinical recovery from esophageal dysfunction after remission of MG in a dog. Further, this is the first HRM documentation of how esophageal muscles overcome a nonrelaxing LES in dogs. Therefore, it appears conceivable that anorexia in a myasthenic dog might be caused by concomitant esophageal achalasia. In humans with type II achalasia, reasons for chest pain as well as its treatment have not been fully understood.\textsuperscript{24} Strategies for treating achalasia comprise medical and surgical options. Pharmacologic treatment with calcium channel blockers, nitrates, phosphodiesterase inhibitors, and botulinum toxin injections may cause prompt reduction in LES pressure, some patients also respond to pneumatic dilations of the LES. Surgical options comprise myotomy and esophagogastric junction stents.\textsuperscript{5} Similar strategies against suspected esophageal discomfort in myasthenic dogs with achalasia-like disease have not been investigated so far, but may include pain medication, as well as feeding soft and slurry food until recovery from MG.

### Acknowledgment

Conflict of Interest: Authors disclose no conflict of interest.

### References

1. Kempf J, Heinrich H, Reusch CE, Kook PH. Feasibility of esophageal high-resolution manometry in awake and sedated dogs. Am J Vet Res 2013;74:895–900.
2. Münster M, Bilzer T, Dettmann K, et al. Assessment of the histological quality of endoscopic biopsies obtained from the canine gastro-esophageal junction. Tierärztl Prax 2012;40:318–324.

3. Cuddon PA. Electrophysiology in neuromuscular disease. Vet Clin North Am Small Anim Pract 2002;32:31–62.

4. Goldblum JR, Whyte RI, Orringer MB, et al. Achalasia. A morphologic study of 42 resected specimens. Am J Surg Pathol 1994;18:327–337.

5. Pandolfino JE, Kahrilas PJ. Presentation, diagnosis, and management of Achalasia. Clin Gastroenterol Hepatol 2013. In press; pii: S1542-3565(13)00176-6.

6. Pandolfino JE. Uncovering hidden information in achalasia using esophageal pressure topography. Gastroenterology 2013;144:681–684.

7. Kjellin AP, Öst AEI, Pope CE. Histology of esophageal mucosa from patients with achalasia. Dis Esophagus 2005;18:257–261.

8. Lehman MB, Clark SB, Ormsby AH, et al. Squamous mucosal alterations in esophagectomy specimens from patients with end-stage achalasia. Am J Surg Pathol 2001;25:1413–1418.

9. Shelton GD. Routine and specialized laboratory testing for the diagnosis of neuromuscular diseases in dogs and cats. Vet Clin Pathol 2010 Sep;39:278–295.

10. Marouani I, Kraoua I, Benrhouma H, et al. Seronegative myasthenia gravis with bladder dysfunction. Rev Neurol 2012;168:299–300.

11. Kaya C, Karaman MI. Case report: A case of bladder dysfunction due to myasthenia gravis. Int Urol Nephrol 2005;37:253–255.

12. Levine JM, Bergman RL, Coates JR, et al. Myasthenia gravis and hypothyroidism in a dog with meningomyelitis. J Am Anim Hosp Assoc 2005;41:247–251.

13. Michaelsin DM, Korczyn AD, Sokolovsky M. Antibodies to muscarinic acetylcholine receptors in myasthenia gravis. Biochem Biophys Res Commun 1982;104:52–57.

14. Shelton GD. Myasthenia gravis and disorders of neuromuscular transmission. Vet Clin North Am Small Anim Pract 2002;32:189–206.

15. Pandolfino JE, Kwiatek MA, Nealis T, et al. Achalasia: A new clinically relevant classification by high-resolution manometry. Gastroenterology 2008;135:1526–1533.

16. Mann CV, Shorter RG. Structure of the canine esophagus and its sphincters. J Surg Res 1964;4:160–163.

17. Gilbert R, Rattan S, Goyal RK. Pharmacologic identification, activation and antagonism of two muscarine receptor subtypes in the lower esophageal sphincter. J Pharmacol Exp Ther 1984;230:284–291.

18. Hong SJ, Bhargava V, Jiang Y, et al. A unique esophageal motor pattern that involves longitudinal muscles responsible for emptying in achalasia esophagus. Gastroenterology 2010;139:102–111.

19. Eckardt VF, Stauff B, Bernhard G. Chest pain in achalasia: Patient characteristics and clinical course. Gastroenterology 1999;116:1300–1304.

20. Boeckxstaens G, Zaninotto G. Achalasia and esophagogastric junction outflow obstruction: Focus on the subtypes. Neurogastroenterol Motil 2012;24:27–31.

21. Kaminski HJ. Achalasia and myasthenia gravis in a patient with thymoma. Neurology 1999;52:425–426.

22. Llabrés M, Molina-Martínez FJ, Miralles F. Dysphagia as the sole manifestation of myasthenia gravis. J Neurol Neurosurg Psychiatry 2005;76:1297–1300.

23. Roche JC, Jaraula L, Artal J, et al. Aperistalsis esofágica en un paciente con miastenia gravis con disfagia como síntoma de presentación. Neurología 2011;26:503–505.

24. Mittal RK, Hong SJ, Bhargava V. Longitudinal muscle dysfunction in achalasia esophagus and its relevance. J Neurogastroenterol Motil 2013;19:126–136.